ASX Australia Markets Statistics Uninformed Investors

ASX:CHM – Strategic $6.6M Capital Raise to Accelerate Clinical Trial Development

ByUninformed Investors

May 21, 2025 #biotech advancement, #biotech funding, #biotech investment, #biotech progress, #biotech research, #biotechnology, #cancer research, #cancer therapy, #cancer therapy development, #cancer treatment, #cancer treatment development, #cancer treatment innovation, #capital markets, #capital raising, #CAR-T therapy, #cell therapy, #Chimeric Therapeutics, #clinical development, #clinical funding, #clinical innovation, #clinical progress, #clinical studies, #clinical technology, #clinical trials, #drug development, #healthcare advancement, #healthcare development, #healthcare innovation, #healthcare progress, #healthcare research, #healthcare technology, #institutional investment, #medical advancement, #medical development, #medical innovation, #medical investment, #medical progress, #medical research, #medical studies, #medical technology, #NK cells, #oncology research, #pharmaceutical development, #research advancement, #research funding, #research innovation, #therapeutic advancement, #therapeutic development, #therapeutic research, #therapeutic studies, #therapeutic technology

Chimeric Therapeutics has secured significant funding through a strongly supported placement, demonstrating market confidence in its innovative cell therapy programs.

Capital Raising Overview

Component	Detail	Impact
Total Raise	$6.6 million	Program advancement
Share Price	$0.004 per share	50% discount to last trade
New Shares	1.65 billion	Two-tranche structure
Options	1:1 unlisted	Additional funding potential
Cornerstone	US family office	Strategic support

Implementation Structure

Tranche	Amount	Timeline
Tranche 1	$0.657M	May 26, 2025
Tranche 2	$5.943M	Post-EGM July 2025
Options Exercise	Potential upside	8-month expiry
Adviser Options	25 million	Subject to approval

Fund Allocation

Key priorities include:
. CHM CDH17 CAR-T trial advancement
. CORE-NK clinical trials progression
. Working capital enhancement
. Operational support
. Program development
. Research continuation